Dry powder inhalation: past, present and future

…, M Hoppentocht, F Buttini, F Grasmeijer… - Expert opinion on …, 2017 - Taylor & Francis
F Grasmeijer and M Hoppentocht are part-time employees of pureIMS and F Buttini receives
research grants from Chiesi Pharmaceutici SpA, Qualicaps® Europe SAU and Plastiape …

[HTML][HTML] Challenges for pulmonary delivery of high powder doses

…, AH de Boer, HW Frijlink, F Grasmeijer - International journal of …, 2018 - Elsevier
In recent years there is an increasing interest in the pulmonary delivery of large cohesive
powder doses, ie drugs with a low potency such as antibiotics or drugs with a high potency that …

The pharmacokinetics of antibiotics in cystic fibrosis

…, OW Akkerman, F Grasmeijer… - Expert opinion on …, 2021 - Taylor & Francis
Introduction Dosing of antibiotics in people with cystic fibrosis (CF) is challenging, due to
altered pharmacokinetics, difficulty of lung tissue penetration, and increasing presence of …

New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation

F Grasmeijer, AJ Lexmond, M van den Noort… - PloS one, 2014 - journals.plos.org
Fine excipient particles or ‘fines’ have been shown to improve the dispersion performance of
carrier-based formulations for dry powder inhalation. Mechanistic formulation studies have …

[HTML][HTML] Natural and bioinspired excipients for dry powder inhalation formulations

…, WLJ Hinrichs, HW Frijlink, F Grasmeijer - Current Opinion in …, 2021 - Elsevier
… The authors declare the following financial interests/personal relationships which may be
considered as potential competing interests: PureIMS, the employer of F. Grasmeijer, is the …

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine

…, MPG Kluitman, M Kloezen, HW Frijlink, F Grasmeijer - Pharmaceutics, 2019 - mdpi.com
Tuberculosis is the leading cause of death from a single infectious pathogen worldwide.
Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing …

Recent advances in the fundamental understanding of adhesive mixtures for inhalation

F Grasmeijer, N Grasmeijer… - Current …, 2015 - ingentaconnect.com
… An indication in support of this hypothesis was provided in a study by Grasmeijer et al., who
showed that, at certain inhalation … Images A,B, D, E and F are obtained from Grasmeijer et …

[HTML][HTML] A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods

M Luinstra, F Grasmeijer, P Hagedoorn… - European Journal of …, 2015 - Elsevier
Adequate treatment of Parkinson’s patients in off periods with orally administered levodopa
is hindered by a poor bioavailability and a slow onset of action. Hence, there is a need for a …

Mixing time effects on the dispersion performance of adhesive mixtures for inhalation

F Grasmeijer, P Hagedoorn, HW Frijlink, HA de Boer - PloS one, 2013 - journals.plos.org
This paper deals with the effects of mixing time on the homogeneity and dispersion performance
of adhesive mixtures for inhalation. Interactions between these effects and the carrier …

Characterization and formulation of isoniazid for high-dose dry powder inhalation

I Sibum, P Hagedoorn, HW Frijlink, F Grasmeijer - Pharmaceutics, 2019 - mdpi.com
… (C–F) show samples stored for two days at 0%, 58%, 75%, and 90% RH, respectively. … (C–F)
show samples stored for two days at 0%, 58%, 75%, and 90% RH, respectively. …